End-of-day quote
Taipei Exchange
03:30:00 28/06/2024 am IST
|
5-day change
|
1st Jan Change
|
72.5
TWD
|
+0.42%
|
|
+1.68%
|
-13.38%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,166
|
1,171
|
1,117
|
1,052
|
1,537
|
3,655
|
Enterprise Value (EV)
1 |
856.4
|
861.2
|
951
|
929.9
|
1,428
|
2,728
|
P/E ratio
|
20.4
x
|
18.2
x
|
17.6
x
|
21.5
x
|
23.7
x
|
38.4
x
|
Yield
|
4.25%
|
4.62%
|
5.16%
|
4.14%
|
3.91%
|
1.79%
|
Capitalization / Revenue
|
2.83
x
|
2.75
x
|
2.63
x
|
2.56
x
|
3.11
x
|
6.02
x
|
EV / Revenue
|
2.08
x
|
2.02
x
|
2.24
x
|
2.26
x
|
2.89
x
|
4.5
x
|
EV / EBITDA
|
10.8
x
|
9.46
x
|
10.7
x
|
12
x
|
14.3
x
|
22.7
x
|
EV / FCF
|
17.2
x
|
19.2
x
|
-8.95
x
|
93.8
x
|
90
x
|
33.8
x
|
FCF Yield
|
5.8%
|
5.22%
|
-11.2%
|
1.07%
|
1.11%
|
2.95%
|
Price to Book
|
1.39
x
|
1.38
x
|
1.3
x
|
1.24
x
|
1.76
x
|
2.19
x
|
Nbr of stocks (in thousands)
|
30,019
|
30,019
|
30,019
|
30,019
|
30,019
|
43,668
|
Reference price
2 |
38.85
|
39.00
|
37.20
|
35.05
|
51.20
|
83.70
|
Announcement Date
|
28/03/19
|
30/03/20
|
25/03/21
|
31/03/22
|
30/03/23
|
29/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
411.9
|
425.3
|
424
|
411.5
|
494.7
|
606.7
|
EBITDA
1 |
79.21
|
91
|
89.24
|
77.57
|
100.1
|
119.9
|
EBIT
1 |
68.73
|
78.83
|
76.01
|
62.28
|
81.79
|
98.83
|
Operating Margin
|
16.69%
|
18.53%
|
17.93%
|
15.14%
|
16.54%
|
16.29%
|
Earnings before Tax (EBT)
1 |
70.9
|
81.44
|
76.55
|
61.94
|
81.53
|
100.9
|
Net income
1 |
57.28
|
64.47
|
63.56
|
49.1
|
64.85
|
79.7
|
Net margin
|
13.91%
|
15.16%
|
14.99%
|
11.93%
|
13.11%
|
13.14%
|
EPS
2 |
1.900
|
2.140
|
2.110
|
1.630
|
2.160
|
2.179
|
Free Cash Flow
1 |
49.67
|
44.96
|
-106.2
|
9.918
|
15.88
|
80.62
|
FCF margin
|
12.06%
|
10.57%
|
-25.06%
|
2.41%
|
3.21%
|
13.29%
|
FCF Conversion (EBITDA)
|
62.71%
|
49.41%
|
-
|
12.79%
|
15.87%
|
67.22%
|
FCF Conversion (Net income)
|
86.71%
|
69.74%
|
-
|
20.2%
|
24.48%
|
101.15%
|
Dividend per Share
2 |
1.650
|
1.800
|
1.920
|
1.450
|
2.000
|
1.500
|
Announcement Date
|
28/03/19
|
30/03/20
|
25/03/21
|
31/03/22
|
30/03/23
|
29/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
310
|
310
|
166
|
122
|
108
|
927
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
49.7
|
45
|
-106
|
9.92
|
15.9
|
80.6
|
ROE (net income / shareholders' equity)
|
6.85%
|
7.65%
|
7.45%
|
5.75%
|
7.54%
|
6.27%
|
ROA (Net income/ Total Assets)
|
4.6%
|
5.22%
|
4.63%
|
3.66%
|
4.95%
|
4.07%
|
Assets
1 |
1,245
|
1,236
|
1,372
|
1,341
|
1,311
|
1,956
|
Book Value Per Share
2 |
27.90
|
28.20
|
28.60
|
28.30
|
29.00
|
38.30
|
Cash Flow per Share
2 |
10.30
|
10.30
|
9.850
|
6.740
|
5.610
|
24.90
|
Capex
1 |
7.33
|
15.1
|
162
|
37.3
|
59.7
|
33.1
|
Capex / Sales
|
1.78%
|
3.55%
|
38.25%
|
9.06%
|
12.07%
|
5.46%
|
Announcement Date
|
28/03/19
|
30/03/20
|
25/03/21
|
31/03/22
|
30/03/23
|
29/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -13.38% | 100M | | +55.32% | 815B | | +44.05% | 641B | | -6.75% | 352B | | +13.56% | 314B | | +10.68% | 303B | | +16.57% | 242B | | +13.31% | 218B | | +8.48% | 168B | | -2.81% | 159B |
Other Pharmaceuticals
|